PRESS RELEASES

Occam Places CMO at Xenotransplantation Biotech

In May 2025, Occam Global recruited Jay Barth, MD as CMO of eGenesis.

‍Dr. Barth is a serial biotech CMO with rich experience shepherding the clinical progress of novel modalities across diverse disease states. He joins eGenesis from Ascidian Therapeutics, where he led the company’s RNA Exon Editing technology into the clinic. His prior roles include that of CMO for orphan disease pioneer Amicus Therapeutics and SVP of Clinical Development at PTC Therapeutics, where he led a landmark approval for Duchenne Muscular Dystrophy.

Barth earned his B.A. from Columbia University and M.D. from the University of Pennsylvania School of Medicine.

About eGenesis
eGenesis is a George Church company pioneering a genome engineering-based approach to develop safe, effective transplantable organs to end the global organ shortage. In the last year, the company has successfully completed two porcine – human kidney transplants and is using funds from a recently closed $191M Series D round to progress programs in the heart, liver and kidney to the clinic. Investors include Lux Capital, ARCH Ventures, Khosla Ventures, Farallon Capital Management, Leaps by Bayer, Polaris Partners, Catalio Capital Management, and Osage University Partners.